AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Metalloreductase STEAP3 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Metalloreductase STEAP3 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Metalloreductase STEAP3, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Metalloreductase STEAP3. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Metalloreductase STEAP3. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Metalloreductase STEAP3 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Metalloreductase STEAP3
partner:
Reaxense
upacc:
Q658P3
UPID:
STEA3_HUMAN
Alternative names:
Dudulin-2; Six-transmembrane epithelial antigen of prostate 3; Tumor suppressor-activated pathway protein 6; pHyde
Alternative UPACC:
Q658P3; A8K6E3; Q4VBR2; Q4ZG36; Q53SQ8; Q7Z389; Q86SF6; Q8NEW6; Q8TDP3; Q8TF03; Q9NVB5
Background:
Metalloreductase STEAP3, also known as Dudulin-2, Six-transmembrane epithelial antigen of prostate 3, Tumor suppressor-activated pathway protein 6, and pHyde, plays a crucial role in iron and copper homeostasis. It functions as an endosomal ferrireductase, facilitating the transferrin-dependent uptake of iron in erythroid cells by reducing Fe(3+) to Fe(2+). Additionally, it can reduce Cu(2+) to Cu(1+), indicating its involvement in copper homeostasis. STEAP3 uses NADP(+) as an acceptor and may interact with p53/TP53 to link apoptosis and cell cycle progression. It is also indirectly involved in exosome secretion.
Therapeutic significance:
The association of Metalloreductase STEAP3 with Anemia, hypochromic microcytic, with iron overload 2, underscores its therapeutic significance. This disease is characterized by abnormal hemoglobin content, severe anemia, and massive hepatic iron deposition, pointing to the critical role of STEAP3 in erythroid iron homeostasis. Understanding the role of Metalloreductase STEAP3 could open doors to potential therapeutic strategies for managing iron-related disorders.
